Clinical trial NCT04522037: Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
Official title: Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patients Hospitalized in the Hospices Civils of Lyon
COVID-19 Disease
Moderate to Severe Dyspnea
Without Resuscitation Objective Management
Keywords: COVID-19 disease
level of care 3 and 4
morphinic treatment
dyspnea
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-08-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 receiving morphinic and not receiving morphinic treatment for COVID-19 disease dyspnea.

Brief summary: Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in palliative care for this type of symptom.

The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These also lead to major exhaustion which can worsen the clinical picture. However, the prescription of morphine is not systematic in front of a respiratory distress table.

The investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in COVID-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4).

The objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in COVID-19 positive participants patients treated in the Hospices Civils of Lyon during COVID-19 pandemic.


Eligibility criteria: Inclusion Criteria:

* Age over 18 years.
* Having had a Covid-19 respiratory disease confirmed by PCR or TDM or anamnestic criterion for patients living in communities for the elderly (respiratory symptomatology suggestive and at least 3 cases confirmed in the living environment).
* Having had respiratory severity criteria: respiratory distress syndrome including FR\> 25 / min and oxygen-demand\> 4 L / min to maintain a SpO2\> 90% at inclusion.
* Having had a defined level of care after collegial discussion notified in the file rejecting the external cardiac massage and admission to the intensive care unit (Level 3 and 4 on the protocols of the Hospices Civils de Lyon).
* Collection of non-opposition

Exclusion Criteria:

-

Primary outcomes:
measure: Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment
timeFrame: Hour 0 and Hour 12 after initiation of morphinic treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital de la Croix Rousse / GHN
city: Lyon
country: France
facility: Hôpital Edouard Herriot
city: Pierre-Bénite
country: France
facility: Hôpital Lyon Sud
Study officials:
References: